

93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)

Dated: July 26, 2021.

**Melanie J. Pantoja,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2021-16162 Filed 7-28-21; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institute of Biomedical Imaging and Bioengineering; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the National Institute of Biomedical Imaging and Bioengineering Special Emphasis Panel.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Institute of Biomedical Imaging and Bioengineering Special Emphasis Panel; P41 NCBIB Review F-SEP.

*Date:* October 25–26, 2021.

*Time:* 09:00 a.m. to 4:30 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, Democracy II, 6707 Democracy Blvd., Bethesda, MD 20892 (Virtual Meeting).

*Contact Person:* Dennis Hlasta, Ph.D., Scientific Review Officer, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, 6707 Democracy Blvd., Bethesda, MD 20892, (301) 451-3398, [dennis.hlasta@mail.nih.gov](mailto:dennis.hlasta@mail.nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.866, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, HHS)

Dated: July 23, 2021.

**David W. Freeman,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2021-16161 Filed 7-28-21; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### The National Institutes of Health (NIH) Scientific Workshop on Violence & Related Health Outcomes in Sexual & Gender Minority Communities Open Session

**AGENCY:** National Institutes of Health, HHS.

**ACTION:** Notice.

**SUMMARY:** The National Institutes of Health (NIH) will hold the Phase IV open session for the NIH Scientific Workshop on Violence and Related Health Outcomes in Sexual and Gender Minority (SGM) Communities to enhance our understanding of violence against SGM individuals and identify opportunities in violence-related research. The primary objectives of NIH's Phase IV meeting are: (1) To allow the public to participate, and (2) to further refine research opportunities.

**DATES:** The NIH Scientific Workshop on Violence and Related Health Outcomes in Sexual and Gender Minority Communities Phase IV virtual meeting will be held on Thursday, August 26, 2021, from 12:00–4:00 p.m. Eastern Daylight Time (New York, GMT).

**ADDRESSES:** The meeting will be held virtually via WebEx.

The preliminary agenda and registration are available at <https://tinyurl.com/SGMwkshp>.

**FOR FURTHER INFORMATION CONTACT:** Irene Avila, Ph.D., Assistant Director, Sexual & Gender Minority Research Office (SGMRO), [avilai@mail.nih.gov](mailto:avilai@mail.nih.gov), 301-594-9701.

**SUPPLEMENTARY INFORMATION:**

*Background:* “Sexual and gender minority” is an umbrella term that includes, but is not limited to, individuals who identify as lesbian, gay, bisexual, asexual, transgender, Two-Spirit, queer, and/or intersex. Individuals with same-sex or -gender attractions or behaviors and those with a difference in sex development are also included. These populations also encompass those who do not self-identify with one of these terms but whose sexual orientation, gender identity or expression, or reproductive development is characterized by non-binary constructs of sexual orientation, gender, and/or sex.

In accordance with Section 404N of the 21st Century Cures Act (Pub. L. 114-255), the Director of NIH shall encourage research on SGM populations. The Sexual and Gender Minority Research Office (SGMRO)

coordinates SGM-related research and activities by working directly with NIH Institutes, Centers, and Offices. The Office was officially established in September 2015 within the Division of Program Coordination, Planning, and Strategic Initiatives (DPCPSI) in the NIH Office of the Director and has the following operational goals: (1) Advance rigorous research on the health of SGM populations in both the extramural and intramural research communities; (2) expand SGM health research by fostering partnerships and collaborations with a strategic array of internal and external stakeholders; (3) foster a highly skilled and diverse workforce in SGM health research; and (4) encourage data collection related to SGM populations in research and the biomedical research workforce. The Scientific Workshop on Violence and Related Health Outcomes in Sexual and Gender Minority Communities represents an important step in pursuing these goals specifically in the field of violence research.

#### The NIH Scientific Workshop on Violence and Related Health Outcomes in Sexual and Gender Minority Communities Phase IV Public Meeting Details

The NIH Scientific Workshop on Violence and Related Health Outcomes in Sexual and Gender Minority Communities invites stakeholders throughout the scientific research community, clinical practice communities, patient and family advocates, scientific or professional organizations, federal partners, internal NIH stakeholders, and other interested members of the public to participate and provide comments, questions, or feedback at the workshop. The goal of the meeting is to identify opportunities in violence-related research. Public input will serve as a valuable element in the development of the final proposed research opportunities.

This notice serves as the announcement for the fourth and final phase of the Scientific Workshop on Violence and Related Health Outcomes in Sexual and Gender Minority Communities. Phase I was the Request for Information (RFI) <https://www.federalregister.gov/documents/2020/11/25/2020-26094/request-for-information-on-research-opportunities-related-to-the-national-institutes-of-health> published in November 2020. The summary of the comments received can be found on the <https://dpcpsi.nih.gov/sgmro> website. Phase II was a session on the state of the science for violence research affecting SGM communities (a recording will be

available after August 26, 2021). The meeting applied an ecological model focusing on family of origin abuse across the lifespan, victimization by peers and friends, romantic and sexual partner violence, and community violence. Phase III included working groups to identify and describe research opportunities to further understand the role of violence in the health of SGM individuals. The working groups were comprised of these five domains:

- Demographics and Epidemiology
- Risk Factors and Pathways
- Preventive Interventions
- Treatment-focused Interventions
- Ethics and Logistical Challenges

Phase IV will involve moderated discussions with the presenters from the Phase III working groups to refine research opportunities needed to further our understanding of violence in SGM communities. Audience feedback, comments, and questions during this session will help further refine the proposed research opportunities.

Dated: July 21, 2021.

**Lawrence A. Tabak,**

*Principal Deputy Director, National Institutes of Health.*

[FR Doc. 2021-16190 Filed 7-28-21; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Center for Scientific Review; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* Center for Scientific Review Special Emphasis Panel; Signaling and Molecular Endocrinology.

*Date:* August 23, 2021.

*Time:* 3:00 p.m. to 5:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Telephone Conference Call).

*Contact Person:* Latha Meenalochana Malaiyandi, Ph.D. Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 812Q, Bethesda, MD 20892, (301) 435-1999, [malaiyandilm@csr.nih.gov](mailto:malaiyandilm@csr.nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: July 23, 2021.

**Tyeshia M. Roberson-Curtis,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2021-16112 Filed 7-28-21; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HOMELAND SECURITY

### U.S. Customs and Border Protection

[CBP Dec. 21-12]

#### COBRA Fees To Be Adjusted for Inflation in Fiscal Year 2022

**AGENCY:** U.S. Customs and Border Protection, Department of Homeland Security.

**ACTION:** General notice.

**SUMMARY:** This document announces that U.S. Customs and Border Protection (CBP) is adjusting certain customs user fees and corresponding limitations established by the Consolidated Omnibus Budget Reconciliation Act (COBRA) for Fiscal Year 2022 in accordance with the Fixing America's Surface Transportation Act (FAST Act) as implemented by the CBP regulations.

**DATES:** The adjusted amounts of customs COBRA user fees and their corresponding limitations set forth in this notice for Fiscal Year 2022 are required as of October 1, 2021.

**FOR FURTHER INFORMATION CONTACT:** Tina Ghiladi, Senior Advisor, International Travel & Trade, Office of Finance, 202-344-3722, [UserFeeNotices@cbp.dhs.gov](mailto:UserFeeNotices@cbp.dhs.gov).

#### SUPPLEMENTARY INFORMATION:

##### I. Background

##### A. Adjustments of COBRA User Fees and Corresponding Limitations for Inflation

On December 4, 2015, the Fixing America's Surface Transportation Act (FAST Act, Pub. L. 114-94) was signed into law. Section 32201 of the FAST Act amended section 13031 of the Consolidated Omnibus Budget Reconciliation Act (COBRA) of 1985 (19 U.S.C. 58c) by requiring the Secretary of the Treasury (Secretary) to adjust certain

customs COBRA user fees and corresponding limitations to reflect certain increases in inflation.

Sections 24.22 and 24.23 of title 19 of the Code of Federal Regulations (19 CFR 24.22 and 24.23) describe the procedures that implement the requirements of the FAST Act. Specifically, paragraph (k) in § 24.22 (19 CFR 24.22(k)) sets forth the methodology to determine the change in inflation as well as the factor by which the fees and limitations will be adjusted, if necessary. The fees and limitations subject to adjustment, which are set forth in appendix A and appendix B of part 24, include the commercial vessel arrival fees, commercial truck arrival fees, railroad car arrival fees, private vessel arrival fees, private aircraft arrival fees, commercial aircraft and vessel passenger arrival fees, dutiable mail fees, customs broker permit user fees, barges and other bulk carriers arrival fees, and merchandise processing fees, as well as the corresponding limitations.

##### B. Determination of Whether an Adjustment Is Necessary for Fiscal Year 2022

In accordance with 19 CFR 24.22, CBP must determine annually whether the fees and limitations must be adjusted to reflect inflation. For Fiscal Year 2022, CBP is making this determination by comparing the average of the Consumer Price Index—All Urban Consumers, U.S. All items, 1982-1984 (CPI-U) for the current year (June 2020-May 2021) with the average of the CPI-U for the comparison year (June 2019-May 2020) to determine the change in inflation, if any. If there is an increase in the CPI-U of greater than one (1) percent, CBP must adjust the customs COBRA user fees and corresponding limitations using the methodology set forth in 19 CFR 24.22(k). Following the steps provided in paragraph (k)(2) of § 24.22, CBP has determined that the increase in the CPI-U between the most recent June to May twelve-month period (June 2020-May 2021) and the comparison year (June 2019-May 2020) is 1.94<sup>1</sup> percent. As the increase in the CPI-U is greater than one (1) percent, the customs COBRA user fees and corresponding limitations must be adjusted for Fiscal Year 2022.

<sup>1</sup> The figures provided in this notice may be rounded for publication purposes only. The calculations for the adjusted fees and limitations were made using unrounded figures, unless otherwise noted.